A placebo-controlled randomized double-blind comparative study of AMG 0001 for obstructive arteriosclerosis
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Beperminogene perplasmid (Primary)
- Indications Arteriosclerosis obliterans; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors AnGes MG
- 22 Jan 2018 According to a AnGes MG media release, based on the data of this study, company submitted an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, for the treatment of critical limb ischemia (CLI), a severe condition of peripheral arterial disease.
- 28 Jun 2007 New trial record.